{"id":914495,"date":"2025-12-01T07:15:46","date_gmt":"2025-12-01T12:15:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/"},"modified":"2025-12-01T07:15:46","modified_gmt":"2025-12-01T12:15:46","slug":"metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/","title":{"rendered":"Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference"},"content":{"rendered":"
\n

EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX) (the \u201cCompany\u201d), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that the Company will present new preclinical data supporting the third target, APOC3, in its collaboration with Ionis Pharmaceuticals at the Nature Conference \u201cCracking the Code: Nucleic Acid Medicines Coming of Age\u201d taking place December 8-10, 2025, in Boston, MA.<\/p>\n

\n
\n Nature Conference \u201cCracking the Code: Nucleic Acid Medicines Coming of Age\u201d<\/u>
\n <\/strong>\n <\/p>\n

\n Title: <\/strong>CRISPR\/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia<\/p>\n

\n Presenters:<\/strong> Alan Brooks, PhD, Senior Vice President of Research at Metagenomi<\/p>\n

\n Date\/time: <\/strong>Monday, December 8, 2025, at 2:45 p.m. EST<\/p>\n

\n About Metagenomi<\/strong>\n <\/p>\n

Metagenomi is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The Company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Going forward, the Company intends to continue to expand its pipeline by leveraging its proprietary genetic editing capabilities in site specific deletion, integration and correction.<\/p>\n

MGX-001, the Company\u2019s lead, wholly-owned development program in hemophilia A, has demonstrated a preclinical profile potentially competitive with best-in-class treatment options, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A. The Company is also currently pursuing other secreted protein deficiencies leveraging the MGX-001 site-specific genome integration system and partnered assets targeting cardiometabolic diseases. For more information, please visit https:\/\/metagenomi.co<\/a><\/u>.<\/p>\n

\n Cautionary Note Regarding Forward-Looking Statements<\/strong>
\n
This press release contains \u200b\u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as \u200b \u201canticipate,\u201d \u200b \u201cbelieve,\u201d \u200b \u201ccould,\u201d \u201cestimate,\u201d \u200b\u201cexpect,\u201d \u200b\u201cgoal,\u201d \u200b\u201cintend,\u201d \u200b\u201clook forward to,\u201d \u200b\u201cmay,\u201d \u200b\u201cplan,\u201d \u200b\u201cpotential,\u201d \u200b\u201cpredict,\u201d \u200b\u201cproject,\u201d \u200b\u201cshould,\u201d \u200b\u201cwill,\u201d \u200b\u201cwould\u201d and similar expressions include, but are not limited to, any statements relating to our product development programs, including the timing of and our ability to conduct IND-enabling studies and make regulatory filings such as INDs, expectations regarding MGX-001, including the preclinical profile being potentially competitive with best-in-class treatment options and timing to submit the IND\/CTA package, statements regarding the Company\u2019s plans to prioritize its preclinical pipeline and potential for value creation and sustainable growth, statements regarding upcoming milestones including the nomination of development candidates, statements concerning the potential of therapies and product candidates, statements concerning the impact of the organizational restructuring, statements concerning our anticipated cash runway, and any other statements that are not historical facts. Forward-looking statements are based on management\u2019s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of IND submissions and starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation and the current regulatory environment; patent and intellectual property matters; competition; the volatility of capital markets and other adverse macroeconomic factors; as well as other risks described in \u200b\u201cRisk Factors,\u201d in our most recent Form 10-K and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.<\/p>\n

\n Investor Contacts:<\/strong>\n <\/p>\n

Stephen Jasper
Gilmartin Group
stephen@gilmartinir.com<\/a><\/u><\/p>\n

or<\/p>\n

Kiki Patel, PharmD
Gilmartin Group
kiki@gilmartinir.com<\/a><\/u><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX) (the \u201cCompany\u201d), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that the Company will present new preclinical data supporting the third target, APOC3, in its collaboration with Ionis Pharmaceuticals at the Nature Conference \u201cCracking the Code: Nucleic Acid Medicines Coming of Age\u201d taking place December 8-10, 2025, in Boston, MA. Nature Conference \u201cCracking the Code: Nucleic Acid Medicines Coming of Age\u201d Title: CRISPR\/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia Presenters: Alan Brooks, PhD, Senior Vice President of Research at Metagenomi Date\/time: Monday, December 8, 2025, at 2:45 p.m. EST About Metagenomi Metagenomi is … <\/p>\n

Continue reading “Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-914495","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMetagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX) (the \u201cCompany\u201d), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that the Company will present new preclinical data supporting the third target, APOC3, in its collaboration with Ionis Pharmaceuticals at the Nature Conference \u201cCracking the Code: Nucleic Acid Medicines Coming of Age\u201d taking place December 8-10, 2025, in Boston, MA. Nature Conference \u201cCracking the Code: Nucleic Acid Medicines Coming of Age\u201d Title: CRISPR\/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia Presenters: Alan Brooks, PhD, Senior Vice President of Research at Metagenomi Date\/time: Monday, December 8, 2025, at 2:45 p.m. EST About Metagenomi Metagenomi is … Continue reading "Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-01T12:15:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDIzMiM3Mjk4MzY3IzIyNjEwNDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference\",\"datePublished\":\"2025-12-01T12:15:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\\\/\"},\"wordCount\":786,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NDIzMiM3Mjk4MzY3IzIyNjEwNDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\\\/\",\"name\":\"Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NDIzMiM3Mjk4MzY3IzIyNjEwNDE=\",\"datePublished\":\"2025-12-01T12:15:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NDIzMiM3Mjk4MzY3IzIyNjEwNDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NDIzMiM3Mjk4MzY3IzIyNjEwNDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/","og_locale":"en_US","og_type":"article","og_title":"Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference - Market Newsdesk","og_description":"EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX) (the \u201cCompany\u201d), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that the Company will present new preclinical data supporting the third target, APOC3, in its collaboration with Ionis Pharmaceuticals at the Nature Conference \u201cCracking the Code: Nucleic Acid Medicines Coming of Age\u201d taking place December 8-10, 2025, in Boston, MA. Nature Conference \u201cCracking the Code: Nucleic Acid Medicines Coming of Age\u201d Title: CRISPR\/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia Presenters: Alan Brooks, PhD, Senior Vice President of Research at Metagenomi Date\/time: Monday, December 8, 2025, at 2:45 p.m. EST About Metagenomi Metagenomi is … Continue reading \"Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-01T12:15:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDIzMiM3Mjk4MzY3IzIyNjEwNDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference","datePublished":"2025-12-01T12:15:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/"},"wordCount":786,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDIzMiM3Mjk4MzY3IzIyNjEwNDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/","name":"Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDIzMiM3Mjk4MzY3IzIyNjEwNDE=","datePublished":"2025-12-01T12:15:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDIzMiM3Mjk4MzY3IzIyNjEwNDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDIzMiM3Mjk4MzY3IzIyNjEwNDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metagenomi-to-present-preclinical-data-supporting-new-collaboration-target-of-apoc3-with-ionis-pharmaceuticals-at-upcoming-nature-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/914495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=914495"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/914495\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=914495"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=914495"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=914495"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}